Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 2, 2007, Pages 187-196

  Fan, X ^a   Wang, Y ^a   Sun, K ^a   Zhang, W ^a   Yang, X ^a   Wang, S ^a   Zhen, Y ^a   Wang, J ^a   Li, W ^a   Han, Y ^a   Liu, T ^a   Wang, X ^a   Chen, J ^a   Wu, H ^a   Hui, R ^a   Xiangsheng, Cheng ^b   Ruilin, Gao ^b   Depei, Liu ^b   Yuhua, Liao ^b   Xigui, Wu ^b   Daowen, Wang ^b   Meiling, Xu ^b   Deyu, Zheng ^b   Dingliang, Zhu ^b   more..

^a FUWAI HOSPITAL   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN I CONVERTING ENZYME II; ANTIHYPERTENSIVE AGENT; ATENOLOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENE PRODUCT; HYDROCHLOROTHIAZIDE; NIFEDIPINE; POTASSIUM; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ESSENTIAL HYPERTENSION; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; TREATMENT DURATION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CAPTOPRIL; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTENSION; LINKAGE DISEQUILIBRIUM; LIPIDS; MALE; MIDDLE AGED; ODDS RATIO; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 34447547666     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100214     Document Type: Article

References (48)

1. Chobanian, A.V. et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289, 2560-2572 (2003).
2. Sciarrone, M.T. et al. ACE and α-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 41, 398-403 (2003).
3. Cadman, P.E. & O'Connor, D.T. Pharmacogenomics of hypertension. Curr. Opin. Nephrol. Hypertens. 12, 61-70 (2003).
4. Marteau, J.B., Zaiou, M., Siest, G. & Visvikis-Siest, S. Genetic determinants of blood pressure regulation. J. Hypertens. 23, 2127-2143 (2005).
5. Kurland, L. et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type I antagonist treatment in hypertensive patients. J. Hypertens. 19, 1783-1787 (2001).
6. Tipnis, S.R., Hooper, N.M., Hyde, R., Karran, E., Christie, G. & Turner, A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a Captopril-insensitive carboxypeptidase. J. Biol. Chem. 275, 33238-33243 (2000).
7. Donoghue, M. et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87, E1-E9 (2000).
8. Yagil, Y. & Yagil, C. Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension 41, 871-873 (2003).
9. Warner, F.J., Smith, A.I., Hooper, N.M. & Turner, A.J. Angiotensin-converting enzyme-2: a molecular and cellular perspective. Cell. Mol. Life Sci. 61, 2704-2713 (2004).
10. Vickers, C. et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277, 14838-14843 (2002).
11. Ferrario, C.M., Chappell, M.C., Tallant, E.A., Brosnihan, K.B. & Diz, D.I. Counterregulatory actions of angiotensin-(1-7). Hypertension 30, 535-541 (1997).
12. Crackower, M.A. et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822-828 (2002).
13. Gurley, S.B. et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J. Clin. Invest. 116, 2218-2225 (2006).
14. Huang, L. et al. Novel peptide inhibitors of angiotensin- converting enzyme 2. J. Biol. Chem. 278, 15532-15540 (2003).
15. Huentelman, M.J. et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp. Physiol. 90, 783-790 (2005).
16. Reudelhuber, T.L. A place in our hearts for the lowly angiotensin 1-7 peptide? Hypertension 47, 811-815 (2006).
17. der-Sarkissian, S., Huentelman, M.J., Stewart, J., Katovich, M.J. & Raizada, M.K. ACE2: a novel therapeutic target for cardiovascular diseases. Prog. Biophys. Mol. Biol. 91, 163-198 (2006).
18. Katovich, M.J., Grobe, J.L., Huentelman, M. & Raizada, M.K. Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension. Exp. Physiol. 90, 299-305 (2005).
19. Benjafield, A.V., Wang, W.Y. & Morris, B.J. No association of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension. Am. J. Hypertens. 17, 624-628 (2004).
20. Zhong, J. et al. Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome. J. Lab. Clin. Med. 147, 91-95 (2006).
21. Liu, T.B. et al. Association of angiotensin I converting enzyme 2 gene polymorphism with essential hypertension in Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22, 569-571 (2005).
22. Huang, W., Yang, W., Wang, Y., Zhao, Q., Gu, D. & Chen, R. Association study of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms and essential hypertension in northern Han Chinese. J. Hum. Hypertens. 20, 968-971 (2006).
23. Yi, L. et al. Association of ACE ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China. J. Int. Med. Res. 34, 272-283 (2006).
24. Kruglyak, L. Power tools for human genetics. Nat. Genet. 37, 1299-1300 (2005).
25. Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P. & Soubrier, F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86, 1343-1346 (1990).
26. Diez-Freire, C. et al. ACE2 gene transfer attenuates hypertension linked pathophysiological changes in the SHR. Physiol. Genomics 27, 12-19 (2006).
27. Zisman, L.S., Meixell, G.E., Bristow, M.R. & Canver, C.C. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation 108, 1679-1681 (2003).
28. Ferrario, C.M. et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 68, 2189-2196 (2005).
29. Santos, R.A. et al. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res. Bull. 35, 293-298 (1994).
30. Fedorova, L. & Fedorov, A. Introns in gene evolution. Genetica 118, 123-131 (2003).
31. Blackwood, E.M. & Kadonaga, J.T. Going the distance: a current view of enhancer action. Science 281, 60-63 (1998).
32. Lewinsky, R.H., Jensen, T.G., Moller, J., Stensballe, A., Olsen, J. & Troelsen, J.T. T-13910 DNA variant associated with lactase persistence interacts with Oct-1 and stimulates lactase promoter activity in vitro. Hum. Mol. Genet. 14, 3945-3953 (2005).
33. Riviere, G. et al. Angiotensin-converting enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to undernutrition-programmed hypertension in the adult rat. Hypertension 46, 1169-1174 (2005).
34. Harmer, D., Gilbert, M., Borman, R. & Clark, K.L. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 532, 107-110 (2002).
35. Iyer, S.N., Ferrario, C.M. & Chappell, M.C. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31, 356-361 (1998).
36. Ferrario, C.M. et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin- converting enzyme 2. Circulation 111, 2605-2610 (2005).
37. Oudit, G.Y., Crackower, M.A., Backx, P.H. & Penninger, J.M. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc. Med. 13, 93-101 (2003).
38. Psaty, B.M. et al. Diuretic therapy, the a-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 287, 1680-1689 (2002).
39. Bis, J.C. et al. Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am. J. Hypertens. 16, 1011-1017 (2003).
40. Rice, G.I., Jones, A.L., Grant, P.J., Carter, A.M., Turner, A.J. & Hooper, N.M. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 48, 914-920 (2006).
41. Elased, K.M., Cunha, T.S., Gurley, S.B., Coffman, T.M. & Morris, M. New mass spectrometric assay for angiotensin-converting enzyme 2 activity. Hypertension 47, 1010-1017 (2006).
42. Reynolds, K. et al. Geographic variations in the prevalence, awareness, treatment and control of hypertension in China. J. Hypertens. 21, 1273-1281 (2003).
43. Wu, Z. et al. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part I: morbidity and mortality monitoring. Circulation 103, 462-468 (2001).
44. Chiu, R.W. et al. ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome. Clin. Chem. 50, 1683-1686 (2004).
45. Lieb, W. et al. Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy. J. Mol. Med. 84, 88-96 (2006).
46. International HapMap Consortium. A haplotype map of the human genome. Nature 437, 1299-1320 (2005).
47. Frojdo, S. et al. Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy. Diabetologia 48, 2278-2281 (2005).
48. Hamon, M., Fradin, S., Denizet, A., Filippi-Codaccioni, E., Grollier, G. & Morello, R. Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention. Heart 89, 321-325 (2003).